NASDAQ:DEPO - Depomed Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.30
+0.30 (1.20%)
Get New Depomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DEPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DEPO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Depomed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.30.

This chart shows the closing price for DEPO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Depomed. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2018Royal Bank of CanadaSet Price TargetHold$8.00High
7/9/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$7.00 ➝ $10.00Medium
3/23/2018MizuhoReiterated RatingBuy$9.00High
3/2/2018Roth CapitalSet Price TargetBuy$10.00Medium
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$8.00Medium
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00Medium
12/7/2017Piper Jaffray CompaniesReiterated RatingHold$9.00High
12/5/2017MizuhoUpgradeNeutral ➝ Buy$9.00High
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$5.00N/A
11/10/2017UBS GroupBoost Price TargetNeutral$6.00 ➝ $7.00N/A
11/9/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/A
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$8.00 ➝ $6.00N/A
10/27/2017Royal Bank of CanadaSet Price TargetHold$8.00N/A
10/20/2017Royal Bank of CanadaSet Price TargetHold$10.00N/A
10/15/2017Piper Jaffray CompaniesSet Price TargetHold$9.00N/A
10/13/2017MizuhoReiterated RatingNeutral$11.00 ➝ $6.00N/A
9/10/2017Piper Jaffray CompaniesReiterated RatingHold$9.00High
8/9/2017Piper Jaffray CompaniesReiterated RatingNeutral$10.00 ➝ $9.00Medium
8/8/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$12.00 ➝ $5.00High
8/8/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$13.00 ➝ $10.00High
8/8/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$18.00 ➝ $8.00High
7/16/2017Royal Bank of CanadaSet Price TargetHold$13.00Low
6/13/2017Royal Bank of CanadaReiterated RatingHold$13.00Low
5/25/2017MizuhoLower Price TargetNeutral$13.00 ➝ $11.00Medium
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00Medium
5/10/2017Royal Bank of CanadaLower Price TargetSector Perform$19.00 ➝ $13.00Low
5/10/2017Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$11.00 ➝ $10.00High
4/11/2017Janney Montgomery ScottReiterated RatingBuy$26.00Low
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 ➝ $16.00High
3/29/2017Janney Montgomery ScottReiterated RatingBuy$26.00High
3/29/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$22.00 ➝ $19.00High
3/29/2017Cantor FitzgeraldReiterated RatingHold$19.00High
3/29/2017MizuhoLower Price TargetNeutral ➝ Neutral$16.00 ➝ $13.00Low
3/25/2017Royal Bank of CanadaSet Price TargetHold$22.00Low
3/1/2017Cantor FitzgeraldSet Price TargetHold$23.00 ➝ $19.00N/A
2/27/2017Janney Montgomery ScottReiterated RatingBuyN/A
2/23/2017Royal Bank of CanadaReiterated RatingSector Perform$22.00N/A
2/20/2017MizuhoDowngradeBuy ➝ NeutralN/A
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/A
2/14/2017MizuhoDowngradeBuy ➝ Neutral$24.00 ➝ $17.00N/A
1/11/2017Cantor FitzgeraldSet Price TargetHold$23.00N/A
12/12/2016Roth CapitalSet Price TargetBuy$27.00N/A
12/12/2016Piper Jaffray CompaniesDowngradeNeutral ➝ Underweight$17.00 ➝ $14.00N/A
12/4/2016Roth CapitalSet Price TargetBuy$27.00N/A
11/28/2016Roth CapitalSet Price TargetBuy$27.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Depomed logo
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Read More

Today's Range

Now: $7.30
Low: $7.09
High: $7.42

50 Day Range

MA: N/A

52 Week Range

Now: $7.30
Low: $4.31
High: $9.48

Volume

940,193 shs

Average Volume

1,300,311 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Depomed?

The following equities research analysts have issued reports on Depomed in the last twelve months:
View the latest analyst ratings for DEPO.

What is the current price target for Depomed?

0 Wall Street analysts have set twelve-month price targets for Depomed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Depomed in the next year.
View the latest price targets for DEPO.

What is the current consensus analyst rating for Depomed?

Depomed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DEPO.

How do I contact Depomed's investor relations team?

Depomed's physical mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company's listed phone number is (224) 419-7106 and its investor relations email address is [email protected] The official website for Depomed is www.depomedinc.com.